SCHEMBL5535574

SCHEMBL5535574

CCCCCCOC(=O)N1CCN(c2ccc([O])cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.57
LMNA P02545 4/20 0.57
GAA P10253 2/20 0.57
KDM4E B2RXH2 1/20 0.57
SMN1; SMN2 Q16637 5/20 0.51
ALDH1A1 P00352 5/20 0.51
HTT P42858 2/20 0.49
MAPK1 P28482 2/20 0.49
POLB P06746 1/20 0.49
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
HRH2 P25021 1/20 0.46
HRH1 P35367 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541807 0.99 MAPT (0.58) MAPTLMNAGAAKDM4ESMN1; SMN2
SCHEMBL5539965 0.95 MAPT (0.59) MAPTLMNAGAAKDM4ESMN1; SMN2
SCHEMBL5535580 0.90 MAPT (0.72) MAPTLMNAGAAKDM4ESMN1; SMN2
SCHEMBL5536205 0.89 MAPT (0.62) MAPTLMNAGAAKDM4ESMN1; SMN2
SCHEMBL5541814 0.88 MAPT (0.74) MAPTLMNAGAAKDM4ESMN1; SMN2
SCHEMBL5542804 0.84 MAPT (0.77) MAPTLMNAGAAKDM4ESMN1; SMN2
SCHEMBL5539971 0.84 MAPT (0.76) MAPTLMNAGAAKDM4ESMN1; SMN2
SCHEMBL3313011 0.83 MAPT (0.58) MAPTLMNAGAAKDM4ESMN1; SMN2
SCHEMBL1459682 0.82 MAPT (0.57) MAPTLMNAGAAKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL31540771 0.82 MAPT (0.57) MAPTLMNAGAAKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885LMNA 4152/4885GAA 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.